Key Highlights

  • A special Cash Dividend of approximately USD 44 million to USD 48 million is currently expected before the Serapha Bio Merger closes, subject to adjustment based on net cash at closing.
  • Third quarter 2026 net loss was USD 5.4 million, or USD 0.23 per share, compared with USD 13.9 million, or USD 0.62 per share, in the same quarter a year earlier.
  • Research and development expense fell to USD 1.4 million from USD 10.7 million, while general and administrative expense edged up to USD 4.8 million from USD 4.5 million on merger costs.
  • Cash, cash equivalents and short-term investments stood at USD 62.9 million on September 30, 2026, and Serapha holders are expected to own about 96.2% of the combined company.

A Special Dividend Takes Shape Ahead of the Serapha Merger

Boundless Bio (NASDAQ:BOLD) filed its Quarterly Report on November 10, 2026, covering the period ended September 30, 2026. The company, a clinical-stage oncology business, agreed on June 22, 2026 to merge with Serapha Bio, a private company developing an investigational gene editing therapy for Alpha-1 Antitrypsin Deficiency. Before closing, it expects to declare a special cash dividend equal to its estimated net cash above zero, currently about USD 44 million to USD 48 million. Existing holders are expected to own about 3.8% of the combined company on a fully diluted basis. The registration statement became effective on November 3, 2026, but closing still needs stockholder approval from both companies, continued Nasdaq listing and at least USD 200 million of gross financing proceeds raised by Serapha.

Net Loss Narrows as Trials Are Wound Down

The third quarter net loss was USD 5.4 million (GAAP), against USD 13.9 million, and the nine-month net loss was USD 42.6 million versus USD 45.3 million. The company has no products approved and has generated no revenue. Research and Development spending dropped USD 9.2 million after it wound down the KOMODO-1, POTENTIATE and STARMAP trials, and after a workforce cut of about 75% announced in June. In June it also said exposure data did not support continued development of its BBI-940 candidate. General and administrative expense rose on USD 1.4 million of higher professional fees tied to the merger. Interest income was USD 0.6 million, down from USD 1.3 million.

Cash Is Earmarked for the Dividend, Severance and Wind Down Costs

Cash, equivalents and short-term investments of USD 62.9 million are not all free, since the filing lists the dividend, remaining merger costs, termination benefits and wind-down expenses as the main uses. About USD 0.4 million of further termination benefits is expected in the fourth quarter, and about USD 3.8 million of change-in-control severance and bonuses become payable only if the merger closes. The company also paid USD 10.0 million to exit a San Diego lease. A termination fee of USD 1.0 million may be payable if either party ends the deal, and stockholders will be asked to approve a reverse stock split. If the merger fails, the filing says substantial new funding would be needed to continue operating.

Where Things Stand

The payout reflects a corporate reset rather than operating success. Boundless Bio (NASDAQ:BOLD) has stopped its own drug programs, cut its workforce and ties its future to the Serapha merger, so the dividend is simply its estimated surplus cash, currently USD 44 million to USD 48 million and subject to adjustment. The narrower net loss of USD 5.4 million comes from lower research spending, not new revenue. Next markers are the stockholder votes, Serapha's financing, the reverse stock split, the dividend declaration and record date, and Nasdaq's ex-dividend date.